Aims-To investigate changes in morphology ofthe developmental stages ofEnterocytozoon bieneusi and symptomatic relief observed in AIDS patients after treatment with furazolidone. Methods-Six AIDS patients with symptomatic E bieneusi infection of the small intestine were treated with a course of furazolidone. All patients had a weekly monitoring of parasite shedding in stool by light microscopy during and after treatment. At the end of the treatment, duodenal biopsy specimens obtained from three patients were studied by transmission electron microscopy by two pathologists who were unaware of the patients' treatment.
Results-Al patients showed both clinical and parasitological response with transient clearance or decrease of spore shedding in stool. After treatment, alterations in faecal spores were observed in all patients by light microscopy, and ultrastructural changes in E bieneusi at all stages of the life cycle were demonstrated in biopsy specimens of the three patients who underwent post-treatment endoscopy.
Conclusions-The clinical benefit seen after treatment with furazolidone in six AIDS patients with E bieneusi intestinal infection may be due to damage to the developmental stages causing a partial inhibition to reproduction of the parasite. (3 Clin Pathol 1997; 50:472-476) Keywords: Enterocytozoon bieneusi; furazolidone; parasite morphology; AIDS Enterocytozoon bieneusi is a microsporidian that causes chronic diarrhoea in severely immunocompromised patients with AIDS.' Currently no established therapy is available because none of the available agents lead to eradication of the infection nor significantly affect the life cycle of the parasite; moreover, relapses rapidly occur after treatment is discontinued. '-4 Furazolidone is a synthetic nitrofuran that is active against a broad spectrum of Gram negative and Gram positive bacteria as well as against some intracellular or extracellular [3] [4] [5] , disruption of nuclear membrane, irregularity of nuclear outline, and apparent separation of nuclear membrane from the nucleoplasm were also frequently seen (figs 4 and 5).
Moreover, about half of sporogonial plasmodia seen in the examined fields showed electron dense discs (EDDS) that failed to develop into polar tubes and appeared disorganised, deformed, disrupted, and pale (figs 3-5). Sporoblasts showed disarrangement of nuclear chromatin similar to that observed in sporogonial plasmodia. Most spores had an irregular outline with diastasis between the spore and the enterocyte cytoplasm suggesting shrinking; however, the polar tubes were unchanged (fig 6) .
No alterations in host cell structures were observed in biopsy specimens taken before and after treatment.
Discussion
Furazolidone treatment in six patients with E bieneusi intestinal infection led to symptomatic relief and decrease (or transient absence) of spore shedding in stool. Subsequently, two patients showed clinical and parasitological relapse during the second and third month following discontinuation of therapy; however, clinical and parasitological remission was achieved by a new course of treatment.
Biopsy specimens from the three patients who underwent post-treatment endoscopy showed ultrastructural changes in E bieneusi at all stages of the life cycle, although these were more pronounced for sporogonial plasmodia whose nuclei constantly showed alterations. Many sporogonial plasmodia showed severe changes in EDDS, and most spores showed a distortion in their outline that suggests shrinking.
Although abnormalities of nuclei have been described in E bieneusi after albendazole treatment,3 to our knowledge marked changes in EDDS have not been reported previously. EDDS are essential to the harmful potential of microsporidia, being precursors of polar tubes.'5 Therefore, the impaired development of EDDS found in sporogonial plasmodia probably indicates a proportionally impaired offending activity of E bieneusi. Distortion in spore outline observed in biopsy samples is difficult to explain; however, we can exclude that it was an artefact, as cell organelles surrounding the spores were normal.
The alterations in developmental stages of E bieneusi seen in biopsy specimens by TEM can justify the presence of dysmorphous spores in stool in all patients. To our knowledge, these changes in faecal spores observed by Weber tiplication. This hypothesis is supported by the observed decrease of parasite load in stool and by the subsequent symptomatic relief. Furazolidone, however, was not able to eradicate E bieneusi infection as, in spite of treatment, some parasites accomplished normal development, giving rise to normal spores.
In spite of its small size, this study seems to demonstrate the efficacy of a new drug for the treatment of E bieneusi intestinal microsporidiosis. The observed symptomatic relief due to furazolidone strictly correlated with the morphological changes of the life cycle of the parasite.
